Press Detail





News: Biotest AG: Biotest reaches 2nd milestone in Biotest Next Level expansion project

News: Biotest AG / Key word(s): Miscellaneous
Biotest AG: Biotest reaches 2nd milestone in Biotest Next Level expansion
project

22.06.2017 / 07:00
The issuer is solely responsible for the content of this announcement.



/
PRESSEMITTEILUNG

Biotest reaches 2nd milestone in Biotest Next Level expansion project

- Authorities grant building approval

- Relocation activities of laboratories and offices for production start in
June

Dreieich, 22 June, 2017. Within the Biotest Next Level expansion project,
Biotest will more than double its production capacity at the Dreieich site,
invest over EUR 250 million and create around 300 new jobs. After completion
of the shell construction of Biotest Next Level in October 2015, the second
milestone was reached within the schedule with the building approval. This
is a further step towards the complete commissioning of the new plant, which
will start the regular operation in approximately 2 to 3 years and will
still result in a considerable financial burden during its ramp-up.

The permit for the use of the building is the result of an intensive
examination by the building inspectorate of the district of Offenbach
(Bauaufsicht des Kreises Offenbach).

A prerequisite was, among other things, proof that the systems work
perfectly in respect to safety, such as fire alarm systems, fire
extinguishers and alarm systems - particularly the interaction of all
technical components. Apart from the commitment of the entire project team,
the key to success was the detailed planning of the preparations and the
tests to be carried out in collaboration with authorities and experts.

As a result of the approval, relocation activities in the laboratory as well
as the production offices will be carried out as planned in June 2017.

"By reaching this milestone, we have made a decisive step forward in
achieving the goals of the company, and on behalf of the entire Board, I
would like to thank the whole team for the great performance." stated
Bernhard Ehmer, CEO of Biotest AG.

About Biotest
Biotest is a provider of plasma proteins and biological drugs. With a value
added chain that extends from pre-clinical and clinical development to
worldwide sales, Biotest has specialised primarily in the areas of clinical
immunology, haematology and intensive medicine. Biotest develops and markets
immunoglobulins, coagulation factors and albumins based on human blood
plasma. These are used for diseases of the immune and haematopoietic
systems. In addition Biotest develops monoclonal antibodies in the
indications of cancer of plasma cells and systemic lupus erythematosus which
are produced by recombinant technologies. Biotest has more than 2,500
employees worldwide. The preference shares of Biotest AG are listed in the
SDAX on the Frankfurt stock exchange.

IR contact
Dr. Monika Buttkereit
phone: +49-6103-801-4406
email: investor_relations@biotest.de

PR contact
Dirk Neumüller
phone: +49-6103-801-269
email: pr@biotest.com

Biotest AG, Landsteinerstr. 5, 63303 Dreieich, Germany, www.biotest.com

Ordinary shares: securities' ID No. 522720; ISIN DE0005227201
Preference shares: securities' ID No. 522723; ISIN DE0005227235
Listing: Prime Standard
Open Market: Berlin-Bremen, Düsseldorf, Frankfurt, Hamburg, Hanover, Munich,
Stuttgart

Disclaimer
This document contains forward-looking statements on overall economic
development as well as on the business, earnings, financial and assets
position of Biotest AG and its subsidiaries. These statements are based on
current plans, estimates, forecasts and expectations of the company and are
thus subject to risks and elements of uncertainty that could result in
significant deviation of actual developments from expected developments. The
forward-looking statements are only valid at the time of publication.
Biotest does not intend to update the forward-looking statements and assumes
no obligation to do so.




22.06.2017 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de



Language: English
Company: Biotest AG
Landsteinerstraße 5
63303 Dreieich
Germany
Phone: 0 61 03 - 8 01-0
Fax: 0 61 03 - 8 01-150
E-mail: investor_relations@biotest.de
Internet: http://www.biotest.de
ISIN: DE0005227235, DE0005227201
WKN: 522723, 522720
Indices: SDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover,
Munich, Stuttgart, Tradegate Exchange



End of News DGAP News Service


585173 22.06.2017